GlassScriptPhysician profile
David Rivera Toro
NPI 1487876132
$867.05
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $422 · 2021: $34.21 · 2022: $119.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $176.90 | 2019-2020 | |
| Esperion Therapeutics, INC. | $130.49 | 2020-2022 | |
| Pfizer INC. | $67.46 | 2019 | |
| Amgen INC. | $61.87 | 2019-2020 | |
| Astellas Pharma US INC | $60.36 | 2019-2020 | |
| Amarin Pharma, INC. | $47.23 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $45.52 | 2019-2020 | |
| Eisai INC. | $37.34 | 2020 | |
| Sunovion Pharmaceuticals INC. | $36.43 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.29 | 2020 | |
| Abbvie INC. | $34.21 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.88 | 2019-2020 | |
| Daiichi Sankyo INC. | $31.64 | 2020 | |
| Allergan, INC. | $31.25 | 2020 | |
| Antares Pharma, INC. | $14.34 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $13.19 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.65 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rivera Toro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.